위장췌장 신경내분비종양 : 시장 인사이트, 역학 및 시장 예측(2036년)

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Insights and Trends

• GEP-NET are heterogeneous tumors arising from neuroendocrine cells in the gastrointestinal tract and pancreas, with incidence increasing over recent decades, partly due to enhanced detection and imaging practices while exact rates vary by region and subtype, their rising recognition underscores unmet clinical needs.
• A significant proportion of GEP-NET express somatostatin receptors, particularly in well and moderately differentiated tumors, which underpins the use of somatostatin analogs and peptide receptor radionuclide therapies.
• GEP NETs represent the most common NET subtype, comprising 50-70% of all NETs.
• Surgery, the only curative treatment for GEP-NET, is generally considered a first-line treatment for localized NETs. However, despite advances in diagnostics, GEP-NET are often not identified for up to 5-7 years after clinical symptoms appear, as the symptoms are not specific.
• Radiomedix and Orano Med are developing AlphaMedix, the first radioligand therapy to receive BTD. AlphaMedix has demonstrated a response rate of 62.5% in GEP-NET patients who had not previously undergone peptide receptor radionuclide therapy (PRRT) with LUTATHERA.
• The development of innovative therapies, particularly radioligand treatments and alpha emitter-based therapies, is driving growth in the GEP-NET market. On the other hand, the complex nature of GEP-NET, combined with challenges in drug manufacturing and administration, poses significant barriers to market entry and growth. Additionally, the impact of generic competition impacts the sales of approved drugs.
• Radioligand therapies continue to advance as LUTATHERA has demonstrated meaningful progression free survival benefits and is approved for somatostatin receptor-positive GEP-NET in adults.
• Ongoing clinical research into targeted therapies and combination regimens continues to expand the therapeutic landscape like RYZ101 is an emerging radioligand therapy designed to deliver targeted alpha radiation to somatostatin receptor-expressing tumors.
• Key Companies involved in the emerging treatment landscape of GEP-NET are ITM Isotope Technologies Munich, Camurus AB, RadioMedix, and others.

DelveInsight's 'Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the GEP-NET, historical and forecasted epidemiology, as well as the GEP-NET market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, GEP-NET patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in GEP-NET and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Market

Increasing Incidence and Early Diagnosis

The rising incidence of GEP-NET, coupled with advanced diagnostics like endoscopic ultrasound (EUS) and, multi-phase computed tomography (CT), has improved detection rates, expanding the treatable patient pool.

Robust R&D and Emerging Pipeline

Pharmaceutical investment is accelerating the development of new therapies for GEP-NET. This is driving innovation in targeted treatments, peptide receptor radionuclide therapy (PRRT), and precision medicine approaches.

Rising Disease Awareness

Increased awareness among clinicians and better patient diagnosis rates, supported by updated clinical guidelines, are accelerating treatment adoption.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Understanding and Treatment Algorithm

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Overview and Diagnosis

GEP-NET are rare, heterogeneous cancers of the pancreas and gastrointestinal tract. Their complexity and late-stage presentation require individualized treatment based on tumor grade, location, hormone activity, and patient symptoms, with management primarily focused on advanced and metastatic disease. Despite advances in diagnostics, GEP-NET are often not identified for up to 5-7 years after clinical symptoms appear, as the symptoms are not specific.

Diagnosis of GEP-NET relies on a combination of biochemical testing, imaging, and sometimes genetic evaluation. Common biochemical markers include chromogranin A, pancreatic hormones (insulin, gastrin, glucagon), and serotonin metabolites such as 5-HIAA in urine, depending on tumor functionality. Imaging studies such as contrast-enhanced CT and MRI are used to localize primary tumors and assess metastatic spread.

Current Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Treatment Landscape

Surgery, the only curative treatment for GEP-NET, is generally considered a first-line treatment for localized NETs. For advanced, metastatic, or unresectable disease, treatment options include peptide receptor radionuclide therapy (PRRT) with LUTATHERA, somatostatin analogs such as octreotide and lanreotide to control hormone-related symptoms and tumor growth, targeted therapies like everolimus and sunitinib for pancreatic NETs, and cytotoxic chemotherapy (temozolomide or capecitabine-based regimens) for high-grade tumors.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Unmet Needs

The section "unmet needs of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Diagnostic delays and disease presentation

2. Treatment resistance & disease progression

3. Resistance to standard therapies

4. Gaps in long-term disease management, and others.....

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Epidemiology

Key Findings from GEP-NET Epidemiological Analysis and Forecast

• The US contributed to the highest incident cases of NETs. The total incident cases of NETs in the United States in 2025 were 31,000.
• According to the secondary search, net project, the incidence of malignant GEP-NET during 2000-2007 was 1.7 per 100,000 population per year in Europe, corresponding to an estimated 26,000 new cases.
• As per the secondary sesrch, the annual incidence of the disease was 6.47 cases per 100,000 population, with an adjusted prevalence of 0.052%. The mean age at diagnosis was 58 +- 15 years, and the sex distribution was nearly equal, with 51% men and 49% women in Spain.
• Surgical resection of the primary tumor was performed in 66% of patients. Histopathological grading showed that most tumors were well differentiated, with 73% classified as Grade 1 (G1), 22% as Grade 2 (G2), and 5% as Grade 3 (G3).
• The most common primary tumor site was the pancreas (52%), followed by the jejunum-ileum (23%). At the time of diagnosis, 24% of patients presented with distant metastases, most frequently involving the liver (44%), peritoneum (25%), or multiple organs (22%). The majority of tumors were sporadic and non-functional.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Drug Analysis & Competitive Landscape

The GEP-NET drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase III-I clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the GEP-NET treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the GEP-NET therapeutics market.

Approved Therapies for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

LUTATHERA (lutetium Lu 177 DOTATATE): Novartis

LUTATHERA, is indicated for adult patients with somatostatin receptor-positive GEP-NET. Peptide receptor radionuclide therapy (PRRT), either with 90-Yttrium-labeled compounds or with LUTATHERA (lutetium-177 oxodotreotide) is approved for supply in Australia and is listed on the Australian Register of Therapeutic Goods (ARTG) under ARTG number 455452, with a registration date of November 2025. In September 2017, the EMA approved LUTATHERA for the treatment of GEP-NET. This is the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NET.

SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals

SOMATULINE DEPOT is a SSA indicated for the treatment of adult patients with unresectable well or moderately differentiated, locally advanced, or metastatic GEP-NET to improve progression-free survival. The drug is also approved for the treatment of adults with carcinoid syndrome by reducing the frequency of short-acting SSA rescue therapy. The drug is administered subcutaneously.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Pipeline Analysis

ITM-11 (n.c.a. 177Lu-edotreotide): ITM Isotope Technologies Munich

ITM-11 (n.c.a. 177Lu-edotreotide), being developed by ITM Isotope Technologies Munich, is an innovative targeted radionuclide therapy agent consisting of two components: firstly, Edotreotide (DOTATOC). It is currently being investigated in two Phase III clinical trials, COMPETE (GEP-NET G1/G2) and COMPOSE (GEP-NET G3/G4). While COMPETE is evaluating ITM-11 for the treatment of patients with Grade 1 and Grade 2 GEP-NET, the radiopharmaceutical candidate is also being investigated in COMPOSE, for patients with well-differentiated high Grade 2 and Grade 3 GEP-NET. ITM Isotope Technologies Munich announced that the FDA completed its filing review and accepted the company's New Drug Application for 177Lu-edotreotide.

CAM2029: Camurus AB

CAM2029, being developed by Camurus AB, is a ready-to-use, long-acting, subcutaneous depot of octreotide under development to treat rare diseases, acromegaly, GEP-NET, and polycystic liver disease (PLD). Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and octreotide exposure with the potential for improved treatment efficacy, compared to current market leading products. CAM2029 is designed to enable easy self-administration, including the option of a pre-filled pen device. The drug is currently being evaluated in a Phase III SORENTO study (Subcutaneous Octreotide Randomized Efficacy in Neuroendocrine Tumors) in patients with GEP-NET. According to the company's presentation, they anticipated to present PFS readout data of Phase III (SORENTO) clinical trial in mid to late 2026.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Key Players, Market Leaders and Emerging Companies

• Novartis
• Pfizer
• Exelixis
• Ipsen Biopharmaceuticals
• ITM Isotope Technologies Munich
• Camurus AB
• Bristol Myers Squibb
• RayzeBio, and others

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Drug Updates

• According to the Camurus AB's 2026 presentation, results from the Phase III (SORENTO) trial are expected to be presented in 2026.
• In March 2025, US FDA approved cabozantinib (CABOMETYX, RayzeBio, Inc.) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
• In November 2025, ITM Isotope Technologies Munich announced that the FDA completed its filing review and accepted the company's New Drug Application for 177Lu-edotreotide (also known as ITM-11 or 177Lu-edotreotide). 177Lu-edotreotide is ITM's proprietary, synthetic, targeted radiotherapeutic investigational agent for the treatment of GEP-NET. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 28, 2026.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Market Outlook

The GEP-NET market is undergoing a steady shift as deeper insights into tumor biology and receptor expression patterns reshape treatment approaches. Historically characterized by slow-growing but complex disease behavior, GEP-NET management is now benefiting from advances in targeted pathways, including mTOR inhibition and somatostatin receptor directed strategies. These developments are improving disease stabilization and delaying progression, particularly in patients with well-differentiated tumors.

At the same time, radioligand-based therapies continue to evolve, with ongoing refinements in peptide receptor targeting and radionuclide design aimed at enhancing therapeutic precision, as seen with agents such as LUTATHERA and Iodine-131 metaiodobenzylguanidine (131I-MIBG). The clinical pipeline is expanding with novel agents, including next-generation receptor-targeted compounds, angiogenesis inhibitors such as sunitinib, and combination regimens designed to address resistance and tumor heterogeneity. Improvements in functional imaging, including Ga-68 DOTATATE PET/CT, and biomarker research are also enabling more accurate disease monitoring and treatment selection.

Overall, growing clinical interest, increasing diagnosis rates, and continued innovation in targeted and radioligand therapies are expected to support sustained growth in the GEP-NET market across major regions.

• Radioligand therapies and targeted agents are expected to remain key drivers of market expansion.
• Emerging pipeline candidates focusing on receptor targeting, angiogenesis, and combination approaches such as surufatinib, and 177Lu-edotreotide are anticipated to increase competition and shape future treatment strategies.

Drug Class/Insights into Leading Emerging and Marketed Therapies in GEP-NET (2022-2036 Forecast)

The GEP-NET market comprises radioligand therapies, and small molecules, each targeting different aspects of GEP-NET.

• Radioligand therapies: LUTATHERA and emerging agents such as 177Lu-edotreotide and [212Pb]VMT-a-NET represent targeted radiopharmaceutical approaches for somatostatin receptor-positive neuroendocrine tumors, delivering cytotoxic radiation directly to tumor cells through peptide receptor radionuclide therapy (PRRT) or next-generation alpha-emitting platforms.
• Small molecules: Approved therapy such as sunitinib (SUTENT) along with pipeline candidates including surufatinib and cabozantinib target key pathways like mTOR signaling, angiogenesis, and somatostatin receptor modulation to inhibit tumor growth and progression.

Small molecules define a major area of ongoing innovation, while radioligand therapies remain clinically established, together driving both current treatment paradigms and future pipeline expansion.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the GEP-NET drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in GEP-NET is expected to vary based on clinical positioning, mechanism of action, and stage of development. Approved targeted therapy such as LUTATHERA (lutetium Lu 177 DOTATATE) is projected to demonstrate steady uptake, driven established efficacy and physician familiarity in advanced disease settings.

In contrast, pipeline candidates surufatinib is expected to follow a moderate uptake trajectory, reflecting its investigational status and gradual adoption as clinical evidence emerges.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Therapies Price Scenario & Trends

Pricing and analogue assessment of GEP-NET therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Approved Drugs

If the patient has private insurance, they could be eligible for Co-Pay Plus and pay as little as USD 25 for their LUTATHERA treatment. Limitations apply - Up to USD 15,000 throughout the treatment. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Novartis reserves the right to rescind, revoke, or amend this program without notice.

Industry Experts and Physician Views for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

To keep up with GEP-NET market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the GEP-NET emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in GEP-NET, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at country level. Centers such as the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center, National Institutes of Health in the USA, and MD Anderson Cancer Center Madrid, etc. were contacted.Their opinion helps understand and validate current and emerging GEP-NET therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in GEP-NET.

Germany "Resection of the disease continues to be a treatment for patients with well-differentiated GEP- NETs and is still conducted in more than 70% of patients with these tumors. However, the recurrence rate for patients who received a resection is 100% at 10 years, changing the treatment paradigm as this was previously considered a curative therapy."

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of GEP-NET, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of GEP-NET, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the GEP-NET market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM GEP-NET market.

Report Insights

• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Patient Population Forecast
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Therapeutics Market Size
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Pipeline Analysis
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Market Size and Trends
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Treatment Addressable Market (TAM)
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Competitive Landscape
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Major Companies Insights
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Price Trends and Analogue Assessment
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Therapies Drug Adoption/Uptake
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Therapies Peak Patient Share Analysis

Report Assessment

• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Current Treatment Practices
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Unmet Needs
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Clinical Development Analysis
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Emerging Drugs Product Profiles
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Market attractiveness
• Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the GEP-NET market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of GEP-NET?
• What are the disease risks, burdens, and unmet needs of GEP-NET? What will be the growth opportunities across the 7MM concerning the patient population with GEP-NET?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of GEP-NET? What are the current guidelines for treating GEP-NET in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the GEP-NET market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Key Conferences And Meetings
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Methodology of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

6. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of GEP-NET By Therapies (%) in the 7MM in 2025
• 6.3. Market Share of GEP-NET By Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

• 7.1. Introduction
• 7.2. Types of GEP-NET
• 7.3. Molecular Classification of GEP-NET
• 7.4. Causes
• 7.5. Signs And Symptoms
• 7.6. Diagnosis
  • 7.6.1. Differential Diagnosis
  • 7.6.2. Diagnostic Algorithm
  • 7.6.3. Diagnostic Guidelines
    • 7.6.3.1. NCCN Guidelines for Diagnosis of GEP-NET
    • 7.6.3.1.1. NCCN Guidelines Version 2.2024 Neuroendocrine Tumors (NET) of the Gastrointestinal Tract (Well-Differentiated Grade 1/2), Lung, and Thymus
    • 7.6.3.1.2. NCCN Guidelines Version 2.2024 Well-Differentiated, Grade 3 NET
    • 7.6.3.1.3. NCCN Guidelines Version 2.2024 NETs of the Pancreas (Well-differentiated Grade 1/2)
    • 7.6.3.2. European Neuroendocrine Tumor Society (ENETS) 2023 Guidance Paper for Gastroduodenal NET G1-G3
• 7.7. Treatment and Management
• 7.8. Treatment Algorithm
• 7.9. Treatment Guidelines
  • 7.9.1. NCCN Guidelines for GEP-NET
  • 7.9.2. NCCN Guidelines Version 2.2024 Neuroendocrine Tumors (NET) of the Gastrointestinal Tract (Well-Differentiated Grade 1/2), Lung, and Thymus
  • 7.9.3. NCCN Guidelines: Well-Differentiated, Grade 3 NET
  • 7.9.4. NCCN Guidelines: NETs of the Pancreas (Well-differentiated Grade 1/2)
  • 7.9.5. European Neuroendocrine Tumor Society (ENETS): Guidance Paper for Gastroduodenal NETs G1-G3

8. Epidemiology and Patient Population of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

• 8.1. Key Findings
• 8.2. Assumption and Rationale
• 8.3. Total Incident Cases of GEP-NET in the 7MM
• 8.4. The United States
  • 8.4.1. Total Incident Cases of NET in the United States
  • 8.4.2. Total Incident Cases of GEP-NET in the United States
  • 8.4.3. Grade-specific Incident Cases of GEP-NET in the United States
  • 8.4.4. Functional status Incident Cases of GEP-NET in the United States
  • 8.4.5. Stage-specific Incident Cases of GEP-NET in the United States
  • 8.4.6. SSR Positive Incident Cases of GEP-NET in the United States
  • 8.4.7. Total Treated Cases of GEP-NET
• 8.5. EU4 and the UK
  • 8.5.1. Total Incident Cases of NET in EU4 and the UK
  • 8.5.2. Total Incident Cases of GEP-NET in EU4 and the UK
  • 8.5.3. Grade-specific Incident Cases of GEP-NET in EU4 and the UK
  • 8.5.4. Functional status Incident Cases of GEP-NET in EU4 and the UK
  • 8.5.5. Stage-specific Incident Cases of GEP-NET in EU4 and the UK
  • 8.5.6. SSR Positive Incident Cases of GEP-NET in EU4 and the UK
  • 8.5.7. Total Treated Cases of GEP-NET
• 8.6. Japan
  • 8.6.1. Total Incident Cases of NET in Japan
  • 8.6.2. Total Incident Cases of GEP-NET in Japan
  • 8.6.3. Grade-specific Incident Cases of GEP-NET in Japan
  • 8.6.4. Functional status Incident Cases of GEP-NET in Japan
  • 8.6.5. Stage-specific Incident Cases of GEP-NET in Japan
  • 8.6.6. SSR Positive Incident Cases of GEP-NET in Japan
  • 8.6.7. Total Treated Cases of GEP-NET

9. Patient Journey of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

10. Marketed Therapies

• 10.1. Marketed Competitive Landscape of GEP-NET
• 10.2. LUTATHERA (lutetium Lu 177 DOTATATE): Novartis
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Summary of Pivotal Trials
  • 10.2.5. Analyst Views
• 10.3. SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Summary of Pivotal Trials
  • 10.3.4. Analyst Views

11. Emerging Therapies

• 11.1. Emerging Competitive Landscape of GEP-NET
• 11.2. ITM-11 (n.c.a. 177Lu-edotreotide): ITM Isotope Technologies Munich
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
    • 11.2.3.1. Clinical Trial Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst Views
• 11.3. CAM2029: Camurus AB
  • 11.3.1. Product Description
  • 11.3.2. Clinical Development
    • 1.1.1.1. Clinical Trial Information
  • 11.3.3. Analyst Views

12. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
• 12.3. Conjoint Analysis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Size of GEP-NET in the 7MM
• 12.6. The United States
  • 12.6.1. Total Market Size of GEP-NET in the United States
  • 12.6.2. Market Size of GEP-NET by Therapies in the United States
• 12.7. EU4 and the UK
  • 12.7.1. Total Market Size of GEP-NET in EU4 and the UK
  • 12.7.2. Market Size of GEP-NET by Therapies in EU4 and the UK
• 12.8. Japan
  • 12.8.1. Total Market Size of GEP-NET in Japan
  • 12.8.2. Market Size of GEP-NET by Therapies in Japan

13. Unmet Needs of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

14. SWOT Analysis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

15. KOL Views of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

• 15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

• 16.1. The US
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025
• 16.5. Market Access and Reimbursement of GEP-NET Therapies

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight